Laboratory of Neuro-Trauma and Neurodegenerative Disorders, Tianjin Geriatrics Institute, Tianjin, China.
Key Laboratory of Post-trauma Neuro-repair and Regeneration in the Central Nervous System, Ministry of Education, Tianjin, China.
FASEB J. 2018 Jan;32(1):512-528. doi: 10.1096/fj.201700673R. Epub 2017 Sep 21.
Neuronal inflammation is the characteristic pathologic change of acute neurologic impairment and chronic traumatic encephalopathy after traumatic brain injury (TBI). Inhibiting the excessive inflammatory response is essential for improving the neurologic outcome. To clarify the regulatory mechanism of microglial exosomes on neuronal inflammation in TBI, we focused on studying the impact of microglial exosomal miRNAs on injured neurons in this research. We used a repetitive (r)TBI mouse model and harvested the injured brain extracts from the acute to the chronic phase of TBI to treat cultured BV2 microglia The microglial exosomes were collected for miRNA microarray analysis, which showed that the expression level of miR-124-3p increased most apparently in the miRNAs. We found that miR-124-3p promoted the anti-inflamed M2 polarization in microglia, and microglial exosomal miR-124-3p inhibited neuronal inflammation in scratch-injured neurons. Further, the mammalian target of rapamycin (mTOR) signaling was implicated as being involved in the regulation of miR-124-3p by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses. Using the mTOR activator MHY1485 we confirmed that the inhibitory effect of exosomal miR-124-3p on neuronal inflammation was exerted by suppressing the activity of mTOR signaling. PDE4B was predicted to be the target gene of miR-124-3p by pathway analysis. We proved that it was directly targeted by miR-124-3p with a luciferase reporter assay. Using a PDE4B overexpressed lentivirus transfection system, we suggested that miR-124-3p suppressed the activity of mTOR signaling mainly through inhibiting the expression of PDE4B. In addition, exosomal miR-124-3p promoted neurite outgrowth after scratch injury, characterized by an increase on the number of neurite branches and total neurite length, and a decreased expression on RhoA and neurodegenerative proteins [Aβ-peptide and p-Tau]. It also improved the neurologic outcome and inhibited neuroinflammation in mice with rTBI. Taken together, increased miR-124-3p in microglial exosomes after TBI can inhibit neuronal inflammation and contribute to neurite outgrowth their transfer into neurons. miR-124-3p exerted these effects by targeting PDE4B, thus inhibiting the activity of mTOR signaling. Therefore, miR-124-3p could be a promising therapeutic target for interventions of neuronal inflammation after TBI. miRNAs manipulated microglial exosomes may provide a novel therapy for TBI and other neurologic diseases.-Huang, S., Ge, X., Yu, J., Han, Z., Yin, Z., Li, Y., Chen, F., Wang, H., Zhang, J., Lei, P. Increased miR-124-3p in microglial exosomes following traumatic brain injury inhibits neuronal inflammation and contributes to neurite outgrowth their transfer into neurons.
神经元炎症是创伤性脑损伤(TBI)后急性神经损伤和慢性创伤性脑病的特征性病理变化。抑制过度的炎症反应对于改善神经预后至关重要。为了阐明小胶质细胞外泌体对 TBI 中神经元炎症的调节机制,我们专注于研究小胶质细胞外泌体 miRNA 对损伤神经元的影响。我们使用重复(r)TBI 小鼠模型,并从 TBI 的急性到慢性阶段采集受伤的脑提取物,以处理培养的 BV2 小胶质细胞。收集小胶质细胞外泌体进行 miRNA 微阵列分析,结果显示 miR-124-3p 在 miRNA 中表达水平增加最明显。我们发现 miR-124-3p 促进了小胶质细胞中抗炎的 M2 极化,小胶质细胞外泌体 miR-124-3p 抑制划痕损伤神经元中的神经元炎症。此外,通过基因本体论和京都基因与基因组百科全书途径分析,哺乳动物雷帕霉素靶蛋白(mTOR)信号被认为参与了 miR-124-3p 的调节。使用 mTOR 激活剂 MHY1485,我们证实外泌体 miR-124-3p 对神经元炎症的抑制作用是通过抑制 mTOR 信号的活性来发挥的。通过途径分析预测 PDE4B 是 miR-124-3p 的靶基因。我们通过荧光素酶报告实验证明了它是 miR-124-3p 的直接靶基因。使用过表达 PDE4B 的慢病毒转染系统,我们表明 miR-124-3p 主要通过抑制 PDE4B 的表达来抑制 mTOR 信号的活性。此外,外泌体 miR-124-3p 在划痕损伤后促进了神经突的生长,其特征在于神经突分支数量和总神经突长度增加,RhoA 和神经退行性蛋白[Aβ-肽和 p-Tau]的表达减少。它还改善了 rTBI 小鼠的神经功能预后并抑制了神经炎症。总之,TBI 后小胶质细胞外泌体中 miR-124-3p 的增加可以抑制神经元炎症并促进神经突生长及其向神经元的转移。miR-124-3p 通过靶向 PDE4B 发挥这些作用,从而抑制 mTOR 信号的活性。因此,miR-124-3p 可能是 TBI 后神经元炎症干预的有前途的治疗靶点。操纵小胶质细胞外泌体的 miRNAs 可能为 TBI 和其他神经疾病提供一种新的治疗方法。
Front Cell Dev Biol. 2025-6-30
J Cereb Blood Flow Metab. 2025-6-19
Int J Biol Sci. 2025-6-5
Adv Oncol. 2025-5